TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29572814

Group type: EXPERIMENTAL
Intervention: COMPASS model (an innovative, comprehensive extension of the TRAnsition Coaching for Stroke program)
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Telephone follow-up at 2, 30, and 60 days after discharge; clinic visit within 14 days by a nurse and advanced practice provider
Number of subjects: 6000
Study: 27759780

Group type: EXPERIMENTAL
Intervention: Intravenous Cephazolin (2 g) during anesthetic induction
Number of subjects: 100

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 100
Study: 24815851

Group type: EXPERIMENTAL
Intervention: 20 μg/kg of palifermin
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 40 μg/kg of palifermin
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 60 μg/kg of palifermin
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 22905609

Group type: EXPERIMENTAL
Intervention: Autogenous bone (group A, n=35)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Allogeneic bone (group B, n=33)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: BMP composite bone (group C, n=34)
Number of subjects: 102
Study: 19464394

Group type: EXPERIMENTAL
Intervention: Meta-analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Poorly conducted meta-analyses
Number of subjects: 0
Study: 17552379

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) intervention plus treatment as usual (mask fitting and information)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment as usual only
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) intervention
Number of subjects: 100
Study: 16336061

Group type: EXPERIMENTAL
Intervention: Feedback group (clinicians received clinical feedback reports at intake and at 6 weeks)
Number of subjects: 1374

Group type: COMPARATOR
Intervention: Control group (clinicians received no report)
Number of subjects: 1374
Study: 11994377

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 10193216

Group type: EXPERIMENTAL
Intervention: Intravenous anaesthesia using propofol
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Inhalational anaesthesia using isoflurane
Number of subjects: 68
Study: 8090163

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 392

Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 392
Study: 3294189

Group type: EXPERIMENTAL
Intervention: gallopamil (150 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: nifedipine (30 mg/day)
Number of subjects: 30
Study: 31785444

Group type: EXPERIMENTAL
Intervention: Strength, Hope, and Resources Program for People with PD (SHARP‐PWP)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Delayed intervention group (waitlist control)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Immediate intervention group
Number of subjects: 31
Study: 31108093

Group type: EXPERIMENTAL
Intervention: Standard ablation regimen (1 × 10 J/cm2-clean-1 × 10 J/cm2)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Simple-single ablation regimen (1 × 10 J/cm2-no clean)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Both groups (Standard and Simple-single)
Number of subjects: 104
Study: 28755285

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg twice daily)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379
Study: 26163252

Group type: EXPERIMENTAL
Intervention: Endoscopic olfactory cleft polyp removal (group A)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Observation (cleft polyps left in place, group B)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Comparison between group A and group B
Number of subjects: 17
Study: 24028801

Group type: EXPERIMENTAL
Intervention: Real rTMS (1 Hz)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 18
Study: 22428493

Group type: EXPERIMENTAL
Intervention: Bonfils retromolar fiberscope
Number of subjects: 40

Group type: COMPARATOR
Intervention: Direct vision laryngoscopy (Macintosh blade)
Number of subjects: 40
Study: 19538915

Group type: EXPERIMENTAL
Intervention: Female-specific motivational-enhancement group intervention
Number of subjects: 285

Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 285
Study: 18693835

Group type: EXPERIMENTAL
Intervention: Web-based program (PG)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Reading group (RG)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 91
Study: 15554736

Group type: EXPERIMENTAL
Intervention: 10% phenylephrine in petrolatum
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 10% pseudoephedrine in petrolatum
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 10% ephedrine in petrolatum
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 20% ephedrine in petrolatum
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 10% phenylpropanolamine in petrolatum
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 5% fepradinol in petrolatum
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 1% methoxamine in petrolatum
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 10% oxymetazoline in petrolatum
Number of subjects: 14

Group type: COMPARATOR
Intervention: DMSO (negative control)
Number of subjects: 14
Study: 11331560

Group type: EXPERIMENTAL
Intervention: Younger patients
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Longer duration of illness
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Less time living independently
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Longer time in hospital for psychiatric reasons
Number of subjects: 667
Study: 9399198

Group type: EXPERIMENTAL
Intervention: Zinc phosphate cement (experimental)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Zinc phosphate cement (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (experimental)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Glass ionomer cement (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Resin cement (experimental)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Resin cement (control)
Number of subjects: 60
Study: 8201643

Group type: EXPERIMENTAL
Intervention: 100 mg ofloxacin
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 200 mg norfloxacin
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 125 mg ciprofloxacin
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Postcoital quinolone prophylaxis
Number of subjects: 33
Study: 2953380

Group type: EXPERIMENTAL
Intervention: Metrizoate with mepivacaine
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Metrizoate with saline
Number of subjects: 17

Group type: COMPARATOR
Intervention: Ioxaglate (320 mg I/ml, osmolality 0.58 ml/kg)
Number of subjects: 17
Study: 2381134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sodium chloride (200 mmol/day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sodium citrate (200 mmol Na/day)
Number of subjects: 15
Study: 5440568

Group type: EXPERIMENTAL
Intervention: Salbutamol (200 mug aerosol inhalation)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Isoprenaline (1,000 mug aerosol inhalation)
Number of subjects: 11
Study: 30845818

Group type: EXPERIMENTAL
Intervention: Olanzapine plus samidorphan (5 mg)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Olanzapine plus samidorphan (10 mg)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Olanzapine plus samidorphan (20 mg)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Olanzapine plus placebo
Number of subjects: 309
Study: 28803820

Group type: EXPERIMENTAL
Intervention: INSIGHT (1 unit/day increase in insulin dosage)
Number of subjects: 212

Group type: COMPARATOR
Intervention: EDITION (dose adjusted by investigator at least once weekly)
Number of subjects: 212
Study: 25867912

Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg once daily (OD)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Rifaximin 550 mg twice daily (BD)
Number of subjects: 306
Study: 23982421

Group type: EXPERIMENTAL
Intervention: MRI total score (0-10) for findings at L4/L5 plus L5/S1 including Modic type I and/or II changes, posterior high intensity zone (HIZ), dark/black nucleus pulposus signal, and ≥40% disc height decrease.
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Presence of HIZ at L5/S1.
Number of subjects: 170
Study: 21420594

Group type: EXPERIMENTAL
Intervention: Corneal collagen crosslinking (CXL)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Sham-procedure control group
Number of subjects: 82

Group type: COMPARATOR
Intervention: Fellow-eye control group
Number of subjects: 82
Study: 19709782

Group type: EXPERIMENTAL
Intervention: Strength training (experimental group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 17304780

Group type: EXPERIMENTAL
Intervention: Meclizine
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 15503832

Group type: EXPERIMENTAL
Intervention: Hodgkin's lymphoma survivors
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study: 11240116

Group type: EXPERIMENTAL
Intervention: Visuospatial processing in autistic subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cerebellar influence on spatial attention
Number of subjects: 0
Study: 9743848

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sevoflurane/Propofol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Inhalation induction (Sevoflurane)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bispectral index of 60
Number of subjects: 60
Study: 8173521

Group type: EXPERIMENTAL
Intervention: Fiber-fortified enteral feeding (Jevity) for 7 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Usual enteral feeding
Number of subjects: 11
Study: 3265624

Group type: EXPERIMENTAL
Intervention: New trimethoprim/sulfamethoxazole preparation (Kepinol forte, 160 mg of trimethoprim/800 mg of sulfamethoxazole)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference preparation (customary in trade and registered according to the AMG 1976)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 12
Study: 29295028

Group type: EXPERIMENTAL
Intervention: Experimental vignettes depicting serious types of IPV with male perpetrator and female victim
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Experimental vignettes depicting serious types of IPV with female perpetrator and male victim
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Prior IPV experiences among female respondents
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Gender dynamics manipulations within IPV scenarios
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Prior psychological IPV experiences
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Prior physical IPV experiences
Number of subjects: 599
Study: 28530089

Group type: EXPERIMENTAL
Intervention: Low frequency repetitive transcranial magnetic stimulation (1 Hz rTMS) applied over the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (age-matched non-disabled adults)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Parkinson's disease group (PD)
Number of subjects: 27
Study: 27222510

Group type: EXPERIMENTAL
Intervention: Lixisenatide once daily
Number of subjects: 298

Group type: COMPARATOR
Intervention: Insulin glulisine once daily
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Lixisenatide thrice daily
Number of subjects: 298

Group type: COMPARATOR
Intervention: Insulin glulisine thrice daily
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 298

Group type: COMPARATOR
Intervention: Insulin glulisine
Number of subjects: 298
Study: 25116277

Group type: EXPERIMENTAL
Intervention: Compression stockings (23-32 mmHg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No compression (NCG)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (CG and NCG)
Number of subjects: 80
Study: 22884766

Group type: EXPERIMENTAL
Intervention: Bosutinib 100-600 mg coadministered with ketoconazole 400 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bosutinib 600 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bosutinib 100-600 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bosutinib coadministered with ketoconazole
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 20413736

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day (AT‐10)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day (AT‐80)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cholestyramine 8 g/day plus sitosterol 2.5 g/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All treatments (AT‐10, AT‐80, cholestyramine plus sitosterol)
Number of subjects: 60
Study: 17950677

Group type: EXPERIMENTAL
Intervention: AZD0865 25 mg
Number of subjects: 1521

Group type: EXPERIMENTAL
Intervention: AZD0865 50 mg
Number of subjects: 1521

Group type: EXPERIMENTAL
Intervention: AZD0865 75 mg
Number of subjects: 1521

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg
Number of subjects: 1521

Group type: EXPERIMENTAL
Intervention: AZD0865 and esomeprazole
Number of subjects: 1521
Study: 16215918

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 12377323

Group type: COMPARATOR
Intervention: 10 Gy single‐fraction radiotherapy (RT)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: 20 Gy in five fractions radiotherapy (RT)
Number of subjects: 230
Study: 10343145

Group type: EXPERIMENTAL
Intervention: Triple therapy regimen of pantoprazole 40 mg (twice daily), clarithromycin 500 mg, and amoxicillin 1,000 mg for 1 week
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Triple therapy regimen of pantoprazole, clarithromycin, and amoxicillin
Number of subjects: 57
Study: 8700082

Group type: EXPERIMENTAL
Intervention: Soothing, lyrical music played in the baby's bed during the experimental period
Number of subjects: 20
Study: 1743759

Group type: EXPERIMENTAL
Intervention: Energy-restricted diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 6351517

Group type: EXPERIMENTAL
Intervention: Varidase solution
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 18
Study: 31987919

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Bipolar disorder (BD) diagnosis
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Substance abuse disorder
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Violent victimization
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Add-on strategies (lithium, lamotrigine/carbamazepine, anti-inflammatory drugs)
Number of subjects: 700
Study: 30189820

Group type: EXPERIMENTAL
Intervention: Catheter over needle (CON) system
Number of subjects: 110

Group type: COMPARATOR
Intervention: Catheter through needle (CTN) system
Number of subjects: 110
Study: 27156655

Group type: EXPERIMENTAL
Intervention: Capsule Endoscopy (CE)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 71
Study: 24861540

Group type: EXPERIMENTAL
Intervention: Induced labelling
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Auditory cues (tones)
Number of subjects: 66
Study: 23249635

Group type: EXPERIMENTAL
Intervention: Mixed urinary incontinence
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Severe symptoms
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Stress urinary incontinence
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Moderate severity of symptoms
Number of subjects: 225
Study: 20216318

Group type: EXPERIMENTAL
Intervention: Coronary heart disease (CHD) group
Number of subjects: 2491

Group type: EXPERIMENTAL
Intervention: Cerebrovascular disease (CVD) group
Number of subjects: 2491

Group type: EXPERIMENTAL
Intervention: Cardiac localization of ischemic event
Number of subjects: 2491
Study: 17373638

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg qd
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg bid
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg qd
Number of subjects: 632

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 632
Study: 15842558

Group type: EXPERIMENTAL
Intervention: 2 mg tolterodine bid
Number of subjects: 52

Group type: COMPARATOR
Intervention: 5 mg oxybutynin tid
Number of subjects: 52
Study: 12554247

Group type: EXPERIMENTAL
Intervention: Misoprostol 50 microg (low dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Misoprostol 100 microg (high dose)
Number of subjects: 0
Study: 9527561

Group type: EXPERIMENTAL
Intervention: AAA bone implantation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Modified Widman flap surgery alone (control)
Number of subjects: 14
Study: 7842205

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2132187

Group type: EXPERIMENTAL
Intervention: Transfer from porcine to human insulin
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Transfer from bovine to human insulin
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 108
Study: 74494

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 1026
Study: 31920176

Group type: EXPERIMENTAL
Intervention: Integrated Pest Management (IPM)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 384
Study: 31642244

Group type: EXPERIMENTAL
Intervention: Individualized intervention through the combination of prenatal and postnatal care
Number of subjects: 341

Group type: COMPARATOR
Intervention: Routine nursing care (Control)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Individualized intervention
Number of subjects: 341
Study: 28537012

Group type: EXPERIMENTAL
Intervention: Nutraceutical treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study: 25514619

Group type: EXPERIMENTAL
Intervention: Fish oil-containing lipid emulsions (FO)
Number of subjects: 483

Group type: COMPARATOR
Intervention: Control lipid emulsions (CO)
Number of subjects: 483
Study: 23391196

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 14624

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14624

Group type: EXPERIMENTAL
Intervention: Both Rivaroxaban and Warfarin
Number of subjects: 14624
Study: 20439262

Group type: EXPERIMENTAL
Intervention: Magnetic Navigation System (MNS)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard guidewires
Number of subjects: 31
Study: 19656250

Group type: EXPERIMENTAL
Intervention: Adenosine infusion (20 mg ATP during isoproterenol infusion)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Reassessment at 30 minutes postisolation
Number of subjects: 88

Group type: COMPARATOR
Intervention: Comparison of ATP induction and 30 minutes reassessment
Number of subjects: 88
Study: 17241411

Group type: EXPERIMENTAL
Intervention: 20 to 40 U BTX‐A
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 10 U BTX‐A
Number of subjects: 79
Study: 15010154

Group type: EXPERIMENTAL
Intervention: Knifelight technique
Number of subjects: 26

Group type: COMPARATOR
Intervention: Open approach
Number of subjects: 26
Study: 11396234

Group type: EXPERIMENTAL
Intervention: PAP in patients with pancreatic cancer
Number of subjects: 75
Study: 9506661

Group type: EXPERIMENTAL
Intervention: Cholestyramine treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Folate supplementation (suggested)
Number of subjects: 0
Study: 8794413

Group type: EXPERIMENTAL
Intervention: Ifosfamide 2.0 g/m2 days 1-3, mesna 400 mg/m2 at 0, 4, 6 h days 1-3, cisplatin 33 mg/m2 days 1-3 with G-CSF 5 micrograms/kg SQ day 4 to post day 11.
Number of subjects: 101

Group type: COMPARATOR
Intervention: Etoposide 200 mg/m2 days 1-3, cisplatin 35 mg/m2 days 1-3 with G-CSF 5 micrograms/kg SQ day 4 to post day 11.
Number of subjects: 101
Study: 2297966

Group type: EXPERIMENTAL
Intervention: Slow injection (mean 0.975 ml/s)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Rapid injection (mean 2.575 ml/s)
Number of subjects: 100
Study: 7270561

Group type: EXPERIMENTAL
Intervention: Timolol maleate 10 mg and hydrochlorothiazide 25 mg (T/H)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg (HCTZ)
Number of subjects: 19
Study: 30785765

Group type: EXPERIMENTAL
Intervention: Cold temperature (0 °C) with no active warm-up (CNWU)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Cold temperature (0 °C) with active warm-up (CWU)
Number of subjects: 7
Study: 28494595

Group type: EXPERIMENTAL
Intervention: G‐Coat Plus
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Heliobond
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both G‐Coat Plus and Heliobond
Number of subjects: 60
Study: 25308968

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic radical prostatectomy
Number of subjects: 2506

Group type: COMPARATOR
Intervention: Open radical prostatectomy
Number of subjects: 2506
Study: 23621385

Group type: EXPERIMENTAL
Intervention: 10 seconds inflation time
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2 minutes inflation time
Number of subjects: 20
Study: 21068008

Group type: EXPERIMENTAL
Intervention: L-4F administered by intravenous (IV) infusion for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-4F administered by subcutaneous (SC) injection for 28 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-4F at concentrations of 150, 375, or 1,000 ng/ml added to plasma ex vivo
Number of subjects: 0
Study: 19127438

Group type: EXPERIMENTAL
Intervention: Group-based mantram intervention
Number of subjects: 93

Group type: COMPARATOR
Intervention: Attention-matched control
Number of subjects: 93
Study: 17330282

Group type: EXPERIMENTAL
Intervention: Specialized intervention program run by rheumatologists, following detailed proceedings, lasting 12 months.
Number of subjects: 13077

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 13077